The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
暂无分享,去创建一个
Rong Liu | G. Reyes | B. Malcolm | S. Zhou | Bahige M Baroudy | Sifang Zhou | Bruce A Malcolm | Gregory R Reyes | B. Baroudy | Rong Liu
[1] C. Dash,et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. , 1998, British journal of clinical pharmacology.
[2] C. Cameron,et al. Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin* , 2001, The Journal of Biological Chemistry.
[3] L. Philipson,et al. Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate , 1977, Antimicrobial Agents and Chemotherapy.
[4] E. De Clercq,et al. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds , 1991, Antimicrobial Agents and Chemotherapy.
[5] E. Domingo,et al. Efficient Virus Extinction by Combinations of a Mutagen and Antiviral Inhibitors , 2001, Journal of Virology.
[6] F. Kayser,et al. Transferable Plasmids Mediating Multiple-Antibiotic Resistance in Streptococcus faecalis subsp. liquefaciens , 1977, Antimicrobial Agents and Chemotherapy.
[7] R. K. Robins,et al. Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.
[8] J. Patterson,et al. Mechanism of La Crosse virus inhibition by ribavirin , 1989, Antimicrobial Agents and Chemotherapy.
[9] C. Rice,et al. Efficient initiation of HCV RNA replication in cell culture. , 2000, Science.
[10] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[11] H. Thomas,et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. , 1996, Journal of hepatology.
[12] R. Lanford,et al. Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes , 2001, Journal of Virology.
[13] M. Alter,et al. Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.
[14] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[15] Z. Hong,et al. Mechanisms of Action of Ribavirin in Antiviral Therapies , 2001, Antiviral chemistry & chemotherapy.
[16] C. Cameron,et al. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase , 2001, Current opinion in infectious diseases.
[17] R. J. Bauer,et al. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Silver,et al. Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .
[19] J. B. Antczak,et al. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. , 1989, Virology.
[20] B. Kommerell,et al. Hepatitis C virus replication. , 1992, The New England journal of medicine.
[21] J. Mullins,et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[22] E. Schmidt,et al. Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System , 2002, Journal of Virology.
[23] P. Glue,et al. The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.
[24] M. Eigen. Selforganization of matter and the evolution of biological macromolecules , 1971, Naturwissenschaften.
[25] H J Alter,et al. Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.
[26] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[27] K. O'connell,et al. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription , 1988, Antimicrobial Agents and Chemotherapy.
[28] J. Patterson,et al. Mechanism of action of ribavirin , 1991 .
[29] R. Bartenschlager,et al. Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations , 2001, Journal of Virology.
[30] M. Alter,et al. Epidemiology of Hepatitis C , 2018, Clinical liver disease.
[31] David A. Steinhauer,et al. Mutation Frequencies at Defined Single Codon Sites in Vesicular Stomatitis Virus and Poliovirus Can Be Increased Only Slightly by Chemical Mutagenesis , 1990, Journal of virology.
[32] V. Stollar,et al. Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. , 1981, Virology.
[33] R. Bartenschlager,et al. Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs , 2001, Journal of Virology.
[34] V. Knight,et al. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. , 1985, Antiviral research.
[35] Reyes Gr. Ribavirin: recent insights into antiviral mechanisms of action. , 2001 .
[36] P. McNamara,et al. Pharmacokinetics and Absolute Bioavailability of Ribavirin in Healthy Volunteers as Determined by Stable-Isotope Methodology , 1999, Antimicrobial Agents and Chemotherapy.
[37] Y. Natsumeda,et al. Characterization of human type I and type II IMP dehydrogenases. , 1993, The Journal of biological chemistry.
[38] Pedro R. Lowenstein,et al. Response of Foot-and-Mouth Disease Virus to Increased Mutagenesis: Influence of Viral Load and Fitness in Loss of Infectivity , 2000, Journal of Virology.
[39] G. Davis,et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial , 1997, Hepatology.
[40] C. Cameron,et al. RNA virus error catastrophe: Direct molecular test by using ribavirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] E. Domingo,et al. Molecular indetermination in the transition to error catastrophe: Systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[42] B. Walker,et al. Hepatitis C virus infection. , 2001, The New England journal of medicine.
[43] S. Horwitz,et al. Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.
[44] J. Arnold,et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Medicine.
[45] E. Domingo,et al. Viruses at the edge of adaptation. , 2000, Virology.
[46] R. Xavier,et al. Hepatitis C virus replication is directly inhibited by IFN-α in a full-length binary expression system , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] G. Reyes. Ribavirin: recent insights into antiviral mechanisms of action. , 2001, Current opinion in drug discovery & development.
[48] A. Kwong,et al. Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon , 2000, Antimicrobial Agents and Chemotherapy.
[49] Deborah Chavez,et al. Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons , 2003, Journal of Virology.